Sinclair Pharma PLC (LON:SPH)‘s stock had its “buy” rating restated by stock analysts at Stifel Nicolaus in a research note issued to investors on Wednesday. They presently have a GBX 63 ($0.82) price objective on the specialty pharmaceutical company’s stock. Stifel Nicolaus’ price target indicates a potential upside of 133.33% from the stock’s previous close.

Other analysts have also issued research reports about the stock. Peel Hunt reiterated a “buy” rating and issued a GBX 68 ($0.89) price objective on shares of Sinclair Pharma PLC in a research note on Wednesday. N+1 Singer restated a “buy” rating on shares of Sinclair Pharma PLC in a research note on Wednesday. Royal Bank Of Canada restated an “outperform” rating on shares of Sinclair Pharma PLC in a research note on Thursday, September 15th. Finally, Jefferies Group decreased their price target on shares of Sinclair Pharma PLC from GBX 60 ($0.78) to GBX 55 ($0.72) and set a “buy” rating for the company in a research note on Wednesday, June 15th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of GBX 57 ($0.74).

Shares of Sinclair Pharma PLC (LON:SPH) traded up 0.8811% during trading on Wednesday, hitting GBX 27.2379. 3,529,189 shares of the stock traded hands. The stock has a 50 day moving average price of GBX 29.84 and a 200-day moving average price of GBX 32.69. The stock’s market cap is GBX 135.37 million. Sinclair Pharma PLC has a 1-year low of GBX 26.25 and a 1-year high of GBX 61.33.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

About Sinclair Pharma PLC

Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.

Receive News & Ratings for Sinclair Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma PLC and related companies with's FREE daily email newsletter.